India Drug M&As Seen Continuing For Three Years Until MNCs Dominate
This article was originally published in PharmAsia News
Merger and acquisition fever in India is expected to continue for another two or three years, leading eventually to multinational drug makers having more clout than domestic firms. Analysts and pharma experts believe the MNCs will gain strength vis-à-vis domestic makers on a steady basis until the shift of dominance begins in another three years. M&A activity among Indian drug makers has grown since the first one, the 2006 acquisition of Matrix Laboratories by U.S.-based Mylan Laboratories. Currently, Indian firms still dominate, with 75 percent of the local market share, but analysts see that percentage slowly decreasing. (Click here for more
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.